个性化医疗临床服务中可靶向体细胞突变的量化:超说明书用药考量
本研究回顾性分析Moffitt癌症中心个性化医疗临床服务(PMCS)审核的1072例患者、1131份NGS结果,依据FDA药物标签基因组标志物表识别可靶向突变。结果显示92例(8.6%)符合至少一种标签内用药,103例(9.6%)可考虑至少一种超说明书用药,合计175例(16.3%)携带可操作突变。
要点
- 1072例中175例(16.3%)携带可操作突变,涉及六个基因。
- 92例(8.6%)符合标签内用药,103例(9.6%)可考虑超说明书用药。
- 多数患者为经治晚期疾病,识别额外治疗线具有临床价值。
核心结论
- 175例(16.3%)独特患者携带六个基因的可操作突变,兼具标签内与超说明书用药机会。
- 多数PMCS审核患者为经治晚期疾病且治疗选择有限,识别额外治疗线具有临床实用性。
研究设计与样本
- 回顾性研究,纳入Moffitt癌症中心PMCS审核的1072例患者和1131份NGS结果。
- 利用FDA药物标签中药物基因组生物标志物表识别含基因组标志物的抗癌药物,并查询离散NGS患者数据库。
- 标签内用药定义为在FDA批准癌种中携带可靶向突变而符合用药条件;超说明书用药定义为在非FDA批准癌种中携带可靶向突变而可考虑用药。
主要发现
- 17种靶向ALK、BRAF、BRCA1/BRCA2、EGFR或ERBB2突变的药物符合纳入标准。
- 92例(8.6%)独特患者符合至少一种标签内药物;103例(9.6%)独特患者可考虑至少一种药物的超说明书使用。
- 合计175例(16.3%)独特患者携带六个基因的可操作突变。
临床怎么用
- 临床药师可依据FDA标签基因组标志物表系统审核NGS结果,识别标签内与超说明书用药机会。
- 对经治晚期且治疗选择有限的患者,应评估可操作突变以拓展治疗线数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Moffitt Cancer Center's Personalized Medicine Clinical Service (PMCS) reviews somatic next-generation sequencing (NGS) assay results, provides interpretations, and identifies potential therapeutic options. The number of individuals reviewed by our clinical service who are eligible for on-label or off-label drug therapy based on genetic test results has previously not been quantitated. We determined the number of patients harboring an actionable mutation that would qualify a patient for an on-label drug or consideration for off-label drug treatment. METHODS: The Food and Drug Administration (FDA) Table of Pharmacogenomic Biomarkers in Drug Labeling was utilized to identify anticancer agents containing genomic markers in the Indications and Usage section of the drug label. A database containing discrete NGS patient data was queried retrospectively for those drugs and associated genomic mutations included in this study. On-label was defined as those patients who were eligible for a drug based on harboring a targetable mutation in the FDA-approved cancer type. Off-label was defined as those patients who may be considered for a drug based on harboring a targetable mutation in a non-FDA-approved cancer type. RESULTS: A total of 1072 patients and 1131 NGS results were eligible for study inclusion. Fifty-two patients (4.9%) had results for more than one NGS assay. Seventeen drugs targeting ALK, BRAF, BRCA1/BRCA2, EGFR, or ERBB2 mutations met the study inclusion criteria. Of the entire patient population, 92 (8.6%) unique patients were eligible for at least one on-label drug; off-label use of at least one drug could be considered in 103 (9.6%) unique patients. CONCLUSION: Combining both on-label and off-label opportunities, 175 (16.3%) unique patients had actionable mutations in six genes. Because most patients reviewed by our PMCS have previously treated advanced disease with limited treatment options, identifying additional lines of therapy is of clinical utility.
引用
- Vela CM, Knepper TC, Gillis NK, et al. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. Pharmacotherapy. 2017. PMID: 28235141. doi:10.1002/phar.1917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。